ArticleCancer prevention research (Philadelphia, Pa.)2011
Challenges related to developing serum-based biomarkers for early ovarian cancer detection.
Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy.Cells · 2024Review
- Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning.Communications medicine · 2023Article
- MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway.International journal of molecular sciences · 2021Article
- Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.Proteomes · 2021Review
- The function of LncRNAs and their role in the prediction, diagnosis, and prognosis of lung cancer.Clinical and translational medicine · 2021Review
- Circulating long non-coding RNABiomarker research · 2020Article
- Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.Journal of proteome research · 2019Article
- Review
- Healthy human serum N-glycan profiling reveals the influence of ethnic variation on the identified cancer-relevant glycan biomarkers.PloS one · 2018Article
- Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors.Frontiers in pharmacology · 2018Review
- Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.Cancer research · 2015Review
- RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.Oncotarget · 2015Article
- Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.Scientific reports · 2015Article
- Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.Oncotarget · 2015Article
- Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.Molecular oncology · 2015Article
- Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.Biological chemistry · 2014Article
- Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer.BMC research notes · 2013Article
- Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1α.Anti-cancer drugs · 2013Article
- Why have protein biomarkers not reached the clinic?Genome medicine · 2011Article
- Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression.Journal of ovarian research · 2011Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
Abstract
In this issue of the journal, Cramer and colleagues and Zhu and colleagues report carefully designed phase 3 assessments of candidate ovarian cancer screening biomarkers. The main conclusion is that CA-125 remains the "best of a bad lot"; the new candidates have fallen short of expectations. We review factors impeding the development of an effective ovarian cancer screening strategy, highlight the requirements related to validating proposed screening biomarkers, and emphasize the risks from premature clinical applications of unvalidated tests, all underscoring the need for new research strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.